Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Mefenamic acid
Essential Generics Ltd
M01AG01
Mefenamic acid
250mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 10010100; GTIN: 5050204100056
_Continued over page_ Ponstan Capsules 250 mg Mefenamic acid 6/L/x/1 6/L/x/1 Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, and herbal preparations. Some medicines may be affected by Ponstan or they may affect how well Ponstan will work. Tell your doctor or pharmacist if you are taking: medicines that can increase the chance of getting ulcers or a bleed in the stomach or gut, such as: - corticosteroids used to treat arthritis and inflammation - medicines such as anti-platelet agents, used to thin the blood (e.g. warfarin, aspirin, clopidogrel) - antidepressants called selective serotonin re-uptake inhibitors (SSRIs) (e.g. paroxetine) - any other anti-inflammatory medicines (e.g. diclofenac, celecoxib) aspirin including low doses of aspirin used to prevent your blood from clotting in certain heart conditions medicines used for high blood pressure (e.g. atenolol, ramipril, valsartan) diuretics (water tablets) or heart medicines (e.g. digoxin, sotalol, diltiazem) some diabetic medicines such as (e.g. glipizide, glibenclamide) medicines which suppress the immune system (e.g. ciclosporin, tacrolimus, methotrexate) lithium, a medicine used to treat mood swings and some types of depression a medicine usually prescribed through hospitals, called mifepristone (taken within the last 12 days) quinolone antibiotics (antibiotics used to treat infections) aminoglycoside antibiotics, used under medical supervision in hospitals zidovudine, a medicine used for HIV probenecid, a medicine used in special cases, to protect the kidneys medicines which bind to protein in the blood - (check with your pharmacist). Blood tests Your doctor may test your blood during treatment. Pregnancy and breast-feeding Pregnancy Mefenamic acid will be passed to your unborn baby. It is not known how much it will affect your unborn baby in the first 6 months of pregnancy. DO N Read the complete document
1 NAME OF THE MEDICINAL PRODUCT Ponstan 250 mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 250 mg mefenamic acid. Excipients with known effect Each capsule contains 77.61 mg lactose monohydrate. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Hard capsule. A practically white to greyish or creamy-white powder in a No 1 hard gelatin capsule having an ivory opaque body and powder blue opaque cap imprinted ‘PONSTAN 250’. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic properties, and a demonstrable antipyretic effect. It has been shown to inhibit prostaglandin activity. Indications 1. As an anti-inflammatory analgesic for the symptomatic relief of rheumatoid arthritis ( including Still’s Disease ), osteoarthritis, and pain including muscular, traumatic and dental pain, headaches of most aetiology, post-operative and post-partum pain; pyrexia in children. 2. Primary dysmenorrhoea. 3. Menorrhagia due to dysfunctional causes and presence of an IUD when other pelvic pathology has been ruled out. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). Do not exceed the stated dose. Posology ADULTS 2 capsules (500 mg) three times daily. In menorrhagia to be administered on the first day of excessive bleeding and continued according to the judgment of the physician. In dysmenorrhoea to be administered at the onset of menstrual pain and continued according to the judgment of the physician. ELDERLY (OVER 65 YEARS) As for adults. Whilst no pharmacokinetic or clinical studies specific to the elderly have been undertaken with Ponstan, it has been used at normal dosage in trials which included many elderly patients. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). Read the complete document